Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index; 24 of the 147 sources its claims cite were checked for support.

RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches

Open access

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, posing significant treatment challenges, particularly in its metastatic form (mCRC). This review comprehensively examines the pivotal role of RAS mutations, specifically KRAS and NRAS, which are detected in approximately 40–45% of mCRC cases, and their impact on treatment decisions and patient outcomes. We assess the effectiveness of standard treatments within the RAS mutant population, highlighting the challenges and limitations these therapies face. Recent advancements in targeted therapies, particularly the focus on novel agents such as KRAS G12C inhibitors, including sotorasib and adagrasib, have shown promising efficacy in overcoming resistance to conventional treatments. Furthermore, this review discusses future directions, emphasizing the need for research into non-RAS targets to address the complexities of resistance mechanisms and improve therapeutic outcomes. This review aims to provide a detailed overview of the current treatments and innovative approaches, supporting the development of personalized management strategies for patients with mCRC.

Overview

CoChat Summary

TL;DR

This review summarizes how RAS mutations, found in approximately 40–45% of metastatic colorectal cancer (mCRC), drive resistance to anti-EGFR therapies and shape prognosis. It highlights retained activity of anti-angiogenic agents and emerging KRAS G12C inhibitor combinations, alongside investigational strategies for other RAS variants.

Key findings

  • RAS mutations (mostly KRAS/NRAS) are detected in approximately 40–45% of mCRC; anti-EGFR agents should not be used first-line in KRAS-mutant tumors, and extended RAS testing is needed before targeted therapy.
  • In CodeBreaK-300, sotorasib 960 mg plus panitumumab achieved mPFS 5.6 months and ORR 26%, versus mPFS 3.9 months and ORR 6% for sotorasib 240 mg; the control arm had no objective responses. In KRYSTAL-1, adagrasib monotherapy ORR was 19% (95% CI 8–33) and adagrasib plus cetuximab ORR was 46% (95% CI 28–66); NCCN recommends these combinations for pretreated KRAS G12C mCRC.
  • Anti-angiogenic agents retain efficacy in RAS-mutant tumors: ML18147 showed no significant KRAS interaction for PFS (p = 0.443) or OS (p = 0.126); RAISE showed significant mPFS improvement in RAS-mutant patients (p = 0.021); a meta-analysis of 14 phase III trials found OS interaction p = 0.003 (RAS WT HR 0.78 vs. mutant HR 0.91).
  • Immunotherapy findings differ by MSI status: in CheckMate 142, ORR was 41% in RAS/BRAF wild-type versus 27% in RAS-mutant MSI-H mCRC; in MSS MAYA, temozolomide followed by nivolumab–ipilimumab gave mPFS 7.1 months (95% CI 5.6–8.4), with 72% RAS-mutant patients and no significant ORR difference between RAS mutant and wild-type (p = 0.660).

Methods

  • Narrative review; literature selection described in the Introduction using PubMed, Scopus, and ClinicalTrials.gov, with keywords including “RAS mutation,” “colorectal cancer,” “KRAS,” and “targeted therapy.”
  • Timeframe January 2010 to March 2025; both peer-reviewed original articles and clinical trial results were considered.
  • No formal systematic review protocol, risk-of-bias assessment, or quantitative meta-analysis is reported.

Limitations

  • The paper does not state a formal limitations section; it notes future challenges including equitable access to biomarker testing, cost-related barriers, and expanding molecular profiling infrastructure across diverse clinical settings.
  • Evident from the text: this is a narrative review with a brief literature-selection description, no reported systematic risk-of-bias assessment, and no quantitative synthesis, so conclusions depend on the selected published trials and may not be exhaustive.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/medicina61071202

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 RAS-effector signaling pathways. PKB/Akt, Protein kinase B; ERK, Extracellular signal-regulated kinase; GDP, guanosine diphosphate; GRB2, Growth factor receptor bound protein 2; GTP, Guanosine triphosphate; EGFR, Epithelial growth factor receptor; JNK, c-Jun N-terminal kinases; MEK, Mitogen-activated protein kinase; mTOR, Mammalian target of rapamycin, NF-κB, Nuclear factor-κB; PI3K, Posphatidylinositol 3-kinase; RAF, RAF proto-oncogene serine/threonine-protein kinase; RalGDS, Ral guanine nucleotide dissociation stimulator; RAS: Rat sarcoma; SOS1, Son of sevenless homolog-1.
Figure 1 RAS-effector signaling pathways. PKB/Akt, Protein kinase B; ERK, Extracellular signal-regulated kinase; GDP, guanosine diphosphate; GRB2, Growth factor receptor bound protein 2; GTP, Guanosine triphosphate; EGFR, Epithelial growth factor receptor; JNK, c-Jun N-terminal kinases; MEK, Mitogen-activated protein kinase; mTOR, Mammalian target of rapamycin, NF-κB, Nuclear factor-κB; PI3K, Posphatidylinositol 3-kinase; RAF, RAF proto-oncogene serine/threonine-protein kinase; RalGDS, Ral guanine nucleotide dissociation stimulator; RAS: Rat sarcoma; SOS1, Son of sevenless homolog-1.CC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 6 Not valid · 110 Not checked · 18 Own results and interpretations

75 more claims · 7 with their cited sources checked

Create a free account to see all 149 claims and to verify the 123 references still open.

See all claims — free account
  • It may state two separate claims as one. 66
  • Probably not a substantial claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 110 references

Cited by

See all 16

Metadata

Authors
Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş.
Affiliations
  • Department of Medical Oncology, Gazi University, Ankara 06560, Turkey
  • Department of Medical Oncology, Niğde Research and Training Hospital, Niğde 51100, Turkey
  • Department of Medical Oncology, Medicana International İzmir Hospital, İzmir 35170, Turkey
  • Ege University (TR)
  • Hacettepe University (TR)
Venue
Medicina
Publisher
MDPI AG
Published
2025-06-30
Volume
61
Issue
7
Pages
1202
ISSN
  • 1010-660X (ISSN-L)
  • 1648-9144
OpenAlex
W4411902113
Cited by
10
References
110
Citations by year
2026: 7 · 2025: 3
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • Medicina (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
RAS mutations, KRAS, NRAS, metastatic colorectal cancer, KRAS G12C inhibitors, sotorasib, adagrasib, treatment resistance, targeted therapy, personalized cancer management
MeSH terms
Antineoplastic Agents, Humans, Membrane Proteins, Mutation, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), GTP Phosphohydrolases, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches. https://app.cochat.ai/papers/10.3390/medicina61071202
The paper
Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025). RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches. Medicina. https://doi.org/10.3390/medicina61071202

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.